Sanctuary Advisors LLC Purchases Shares of 6,534 Revolution Medicines, Inc. $RVMD

Sanctuary Advisors LLC acquired a new stake in Revolution Medicines, Inc. (NASDAQ:RVMD) in the second quarter, HoldingsChannel reports. The institutional investor acquired 6,534 shares of the company’s stock, valued at approximately $1,224,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in RVMD. Global Retirement Partners LLC raised its position in Revolution Medicines by 1,002.8% in the fourth quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock worth $32,000 after purchasing an additional 361 shares in the last quarter. Contravisory Investment Management Inc. acquired a new stake in Revolution Medicines during the second quarter valued at approximately $32,000. Torren Management LLC bought a new stake in shares of Revolution Medicines in the 4th quarter valued at approximately $33,000. Johnson Financial Group Inc. bought a new stake in shares of Revolution Medicines in the 2nd quarter valued at approximately $37,000. Finally, Arax Advisory Partners bought a new stake in shares of Revolution Medicines in the 4th quarter valued at approximately $38,000. 94.34% of the stock is owned by institutional investors.

Key Revolution Medicines News

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Landmark FDA approval: RASONQUE is described as the first broad RAS-targeted medicine approved for metastatic pancreatic cancer, addressing a disease with limited treatment options and potentially validating Revolution Medicines’ RAS/MAPK drug-development platform. FDA approval announcement
• Positive Sentiment: Commercial opportunity expands: Analysts said the RASONQUE label creates a sizable opportunity, while RBC viewed the company’s planned launch as rapid. Management’s discussion also emphasized the approval’s implications for broader RAS-driven cancer treatment and future indications. Rasonque label expansion analysis
• Positive Sentiment: Higher analyst targets: Truist raised its price target from $231 to $239 and maintained a Buy rating, while Wedbush increased its target from $201 to $225 and kept an Outperform rating. These revisions reflect improved confidence following the approval. Analyst price target changes
• Neutral Sentiment: Pricing and launch execution will matter: Revolution Medicines priced RASONQUE at approximately $39,800 per month. The price supports substantial revenue potential, but payer coverage, patient access and real-world adoption could influence how quickly the approval translates into sales. Rasonque pricing article
• Negative Sentiment: Insider selling and ongoing losses remain risks: Insider Mark Goldsmith sold 80,000 shares for roughly $16.7 million, reducing his holdings by about 23%. Revolution Medicines also remains unprofitable, and its latest quarterly loss exceeded analyst expectations, so the stock’s valuation depends heavily on successful commercialization and pipeline progress. Insider sale report

Wall Street Analyst Weigh In

Several equities analysts recently commented on RVMD shares. Oppenheimer raised their target price on Revolution Medicines from $230.00 to $260.00 and gave the stock an “outperform” rating in a research report on Thursday. HC Wainwright upped their price target on Revolution Medicines from $195.00 to $280.00 and gave the company a “buy” rating in a research report on Thursday. Raymond James Financial reiterated a “strong-buy” rating and set a $248.00 price objective on shares of Revolution Medicines in a research note on Thursday. TD Cowen raised Revolution Medicines to a “strong-buy” rating in a report on Monday. Finally, Guggenheim boosted their target price on shares of Revolution Medicines from $235.00 to $240.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Revolution Medicines presently has a consensus rating of “Moderate Buy” and a consensus price target of $193.28.

Revolution Medicines Stock Performance

NASDAQ:RVMD opened at $221.15 on Friday. Revolution Medicines, Inc. has a 1 year low of $37.56 and a 1 year high of $224.31. The firm has a 50 day moving average of $192.43 and a 200-day moving average of $148.17. The company has a current ratio of 11.38, a quick ratio of 11.38 and a debt-to-equity ratio of 0.40. The stock has a market capitalization of $47.40 billion, a P/E ratio of -25.07 and a beta of 1.39.

Revolution Medicines (NASDAQ:RVMD) last announced its earnings results on Wednesday, August 5th. The company reported ($3.06) EPS for the quarter, missing the consensus estimate of ($2.04) by ($1.02). During the same period last year, the business earned ($1.31) earnings per share. As a group, sell-side analysts anticipate that Revolution Medicines, Inc. will post -8.82 EPS for the current fiscal year.

Insider Transactions at Revolution Medicines

In other Revolution Medicines news, CFO Jack Anders sold 20,000 shares of the business’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $168.33, for a total value of $3,366,600.00. Following the transaction, the chief financial officer owned 123,269 shares of the company’s stock, valued at approximately $20,749,870.77. The trade was a 13.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Sushil Patel sold 5,580 shares of the business’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $187.99, for a total value of $1,048,984.20. Following the completion of the transaction, the director directly owned 21,656 shares in the company, valued at approximately $4,071,111.44. This represents a 20.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 212,497 shares of company stock worth $38,206,486. 7.60% of the stock is owned by company insiders.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.